We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Method Simplifies Preparation of Tumor Genomic DNA Libraries

By LabMedica International staff writers
Posted on 28 Oct 2019
A method has been described that simplifies preparation of tumor genomic DNA libraries by employing restriction enzymes and in vitro transcription to barcode and amplify genomic DNA prior to library construction.

In general, a genomic library is the collection of the total genomic DNA from a single organism. More...
The DNA is stored in a population of identical vectors, each containing a different insert of DNA. In order to construct a genomic library, the organism's DNA is extracted from cells and then digested with a restriction enzyme to cut the DNA into fragments of a specific size. The fragments are then inserted into the vector using DNA ligase.

Copy number alterations or variations are common features of cancer cells. Within the same tumor, cells belonging to different anatomical areas of the tumor may carry different variations. Tumors with many variations are typically very aggressive and tend to be resistant to treatment.

Current strategies for massively parallel sequencing of tumor genomic DNA mainly rely on library indexing in the final steps of library preparation. This procedure is costly and time-consuming, since a library must be generated separately for each sample. Furthermore, whole-genome amplification requires intact DNA and thus is problematic in fixed tissue samples, in particular formalin-fixed, paraffin-embedded (FFPE) specimens, which still represent a cornerstone in pathology.

To overcome these limitations, investigators at the Karolinska Institutet (Solna, Sweden) developed a method, which they named CUTseq, that combined restriction endonucleases with in vitro transcription (IVT) to construct highly multiplexed DNA libraries for reduced representation genome sequencing of multiple samples in parallel.

The investigators showed that CUTseq could be used to barcode gDNA extracted from both non-fixed and fixed samples, including old archival FFPE tissue sections. They benchmarked CUTseq by comparing it with a widely used method of DNA library preparation and demonstrated that CUTseq could be used for reduced representation genome and exome sequencing, enabling reproducible DNA copy number profiling and single-nucleotide variant (SNV) calling in both cell and low-input FFPE tissue samples.

The investigators demonstrated an application of CUTseq for assessing genetic differences within tumors by profiling DNA copy number levels in multiple small regions of individual FFPE tumor sections. Finally, they described a workflow for rapid and cost-effective preparation of highly multiplexed CUTseq libraries, which could be applied in the context of high-throughput genetic screens and for cell line authentication.

"I expect that CUTseq will find many useful applications in cancer diagnostics," said senior author Dr. Nicola Crosetto, senior researcher in medical biochemistry and biophysics at the Karolinska Institutet. "Multi-region tumor sequencing is going to be increasingly used in the diagnostic setting, in order to identify patients with highly heterogeneous tumors that need to be treated more aggressively. I believe that our method can play a leading role here."

The study was published in the October 18, 2019, online edition of the journal Nature Communications.

Related Links:
Karolinska Institutet


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: AI-powered ctDNA analysis provides clinicians with a new lens to monitor disease evolution (Photo courtesy of Brandon Stelter, Katie Han, Kyle Smith, and Paul Northcott)

AI-Powered Liquid Biopsy Classifies Pediatric Brain Tumors with High Accuracy

Liquid biopsies offer a noninvasive way to study cancer by analyzing circulating tumor DNA in body fluids. However, in pediatric brain tumors, the small amount of ctDNA in cerebrospinal fluid has limited... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: Sophie Paczesny, M.D., Ph.D and her team have made BIOPREVENT freely available for researchers and clinician to test and learn from (Photo courtesy of Cliff Rhodes)

AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear

Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.